Greater China

Chinese biopharmaceutical company Zai Lab has appointed a pair of firms to lead its US listing, as a host of other Mainland companies also prepare to float across the Pacific.

Shandong International Trust Co has returned for a second attempt at a Hong Kong listing, refiling a draft prospectus six months after cancelling its $300m IPO.

John Wade has joined Mizuho Securities as head of debt capital markets for Asia Pacific, based in Hong Kong.

China Merchants Bank Co has received the blessing from the China Banking Regulatory Commission to raise Rmb35bn ($5.25bn) in additional tier one capital from the domestic and foreign markets.

The People’s Bank of China puts preventing systemic risk as a priority in its quarterly policy report, China’s non-financial outbound direct investment (ODI) falls in the first half, and US president Donald Trump wants to start an investigation into potential Chinese violation of US intellectual property policy.

Invitations are out for a HK$2bn ($256m) three year loan for a unit of China Forestry Group Corp.

Ford Automotive Finance (China) is gearing up for its second auto loan ABS transaction of the year in China, with bookbuilding slated for August 17. The carmaker is hoping to take home Rmb4bn ($600.2m) from the deal — a larger size than its last trade.

Nasdaq-listed Chinese biopharmaceutical firm BeiGene has bagged $175m from a follow-on public offering of American Depositary Shares (ADSs).

China Isotope, which filed a listing application for its Hong Kong IPO in June, is aiming to launch the transaction by late September.

21Vianet Group, China Huiyuan Juice Group and Greenland Holding Group managed to steer their dollar outings in the right direction on Thursday, defying any concerns among investors to get their deals past the finish line.

China’s FX reserves grow again in July, Harvest Fund Management lists the first ETF tracking FTSE Russell’s China index on the Shanghai Stock Exchange, and Standard Chartered’s Renminbi Globalisation Index (RGI) falls in June.

China’s new Financial Stability and Development Commission (FSDC), set up in July and integrated into the country’s central bank, reflects the authorities’ desire to change the regulatory set-up. But it is unlikely to lead to an outright merger of regulators.